At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 26 enrolled
Drug / intervention
liposomal bupivacaine +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Evaluation of Diaphragm Movement After an Interscalene Block
In Brief
A Phase 4 clinical trial evaluating liposomal bupivacaine and bupivacaine for Phrenic Nerve Paralysis. Completed, enrolled 26 participants across 1 site.
Detailed Summary
The purpose of this study is to evaluate the movement of the diaphragm after an interscalene block with liposome bupivacaine (LB) compared to interscalene block (IB) with bupivacaine. This study will evaluate if there is a possible prolonged phrenic nerve paralysis when using liposome bupivacaine in an interscalene block, using ultrasound.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsPhrenic Nerve Paralysis
CountriesUnited States
Collaborators--
Timeline
Phase 4CompletedFinished
20192020202120222023202420252026
Enrollment StartAug 2018
First PostedAug 2018
Primary CompletionJun 2020
TodayJul 2026
First PostedAug 17, 2018
Enrollment StartAug 1, 2018
Primary CompletionJun 3, 2020
TodayJul 2, 2026
Enrollment to primary: 1.8 yearsPosted 7.9 years ago
Interventions
liposomal bupivacainedrug
Experimental
bupivacainedrug
Active comparator